vs

Side-by-side financial comparison of RECURSION PHARMACEUTICALS, INC. (RXRX) and SOUTHERN FIRST BANCSHARES INC (SFST). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $31.8M, roughly 1.1× SOUTHERN FIRST BANCSHARES INC). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 26.1%). SOUTHERN FIRST BANCSHARES INC produced more free cash flow last quarter ($29.9M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 22.2%).

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

First Community Bankshares, Inc. is a $2.43 billion bank holding company and the parent company of First Community Bank of Bluefield, Virginia, in the United States. As of 2012 First Community Bank had 45 locations in Virginia, West Virginia, and North Carolina, and two locations operating as Peoples Community Bank in Tennessee. As of April 21, 2023, First Community had $3.6 billion in assets.

RXRX vs SFST — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$31.8M
SFST
Growing faster (revenue YoY)
RXRX
RXRX
+655.6% gap
RXRX
681.7%
26.1%
SFST
More free cash flow
SFST
SFST
$77.2M more FCF
SFST
$29.9M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
22.2%
SFST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RXRX
RXRX
SFST
SFST
Revenue
$35.5M
$31.8M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
40.1%
Net Margin
-304.2%
Revenue YoY
681.7%
26.1%
Net Profit YoY
39.6%
EPS (diluted)
$-0.17
$1.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RXRX
RXRX
SFST
SFST
Q4 25
$35.5M
$31.8M
Q3 25
$5.2M
$31.1M
Q2 25
$19.2M
$28.6M
Q1 25
$14.7M
$26.5M
Q4 24
$4.5M
$25.2M
Q3 24
$26.1M
$23.8M
Q2 24
$14.4M
$23.1M
Q1 24
$13.8M
$21.3M
Net Profit
RXRX
RXRX
SFST
SFST
Q4 25
$-108.1M
Q3 25
$-162.3M
$8.7M
Q2 25
$-171.9M
$6.6M
Q1 25
$-202.5M
$5.3M
Q4 24
$-178.9M
Q3 24
$-95.8M
$4.4M
Q2 24
$-97.5M
$3.0M
Q1 24
$-91.4M
$2.5M
Gross Margin
RXRX
RXRX
SFST
SFST
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
RXRX
RXRX
SFST
SFST
Q4 25
-304.8%
40.1%
Q3 25
-3327.6%
36.4%
Q2 25
-916.8%
30.0%
Q1 25
-1297.9%
26.1%
Q4 24
-4042.4%
27.3%
Q3 24
-377.1%
24.1%
Q2 24
-697.4%
17.0%
Q1 24
-698.4%
15.9%
Net Margin
RXRX
RXRX
SFST
SFST
Q4 25
-304.2%
Q3 25
-3135.3%
27.8%
Q2 25
-894.2%
23.0%
Q1 25
-1373.3%
19.9%
Q4 24
-3935.5%
Q3 24
-367.5%
18.4%
Q2 24
-676.6%
13.0%
Q1 24
-662.4%
11.8%
EPS (diluted)
RXRX
RXRX
SFST
SFST
Q4 25
$-0.17
$1.19
Q3 25
$-0.36
$1.07
Q2 25
$-0.41
$0.81
Q1 25
$-0.50
$0.65
Q4 24
$-0.56
$0.69
Q3 24
$-0.34
$0.54
Q2 24
$-0.40
$0.37
Q1 24
$-0.39
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RXRX
RXRX
SFST
SFST
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$1.1B
$368.7M
Total Assets
$1.5B
$4.4B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RXRX
RXRX
SFST
SFST
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
RXRX
RXRX
SFST
SFST
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
RXRX
RXRX
SFST
SFST
Q4 25
$1.1B
$368.7M
Q3 25
$1.0B
$356.3M
Q2 25
$919.1M
$345.5M
Q1 25
$933.9M
$337.6M
Q4 24
$1.0B
$330.4M
Q3 24
$524.6M
$326.5M
Q2 24
$584.4M
$318.7M
Q1 24
$401.2M
$315.3M
Total Assets
RXRX
RXRX
SFST
SFST
Q4 25
$1.5B
$4.4B
Q3 25
$1.4B
$4.4B
Q2 25
$1.3B
$4.3B
Q1 25
$1.3B
$4.3B
Q4 24
$1.4B
$4.1B
Q3 24
$726.5M
$4.2B
Q2 24
$775.9M
$4.1B
Q1 24
$557.8M
$4.1B
Debt / Equity
RXRX
RXRX
SFST
SFST
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RXRX
RXRX
SFST
SFST
Operating Cash FlowLast quarter
$-46.1M
$30.5M
Free Cash FlowOCF − Capex
$-47.3M
$29.9M
FCF MarginFCF / Revenue
-133.1%
93.8%
Capex IntensityCapex / Revenue
3.5%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M
$62.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RXRX
RXRX
SFST
SFST
Q4 25
$-46.1M
$30.5M
Q3 25
$-117.4M
$14.5M
Q2 25
$-76.4M
$10.5M
Q1 25
$-132.0M
$7.6M
Q4 24
$-115.4M
$25.6M
Q3 24
$-59.2M
$26.3M
Q2 24
$-82.2M
$4.0M
Q1 24
$-102.3M
$-2.9M
Free Cash Flow
RXRX
RXRX
SFST
SFST
Q4 25
$-47.3M
$29.9M
Q3 25
$-117.6M
$14.4M
Q2 25
$-79.6M
$10.4M
Q1 25
$-133.8M
$7.4M
Q4 24
$-116.7M
$24.8M
Q3 24
$-63.8M
$26.1M
Q2 24
$-83.4M
$3.9M
Q1 24
$-109.0M
$-3.2M
FCF Margin
RXRX
RXRX
SFST
SFST
Q4 25
-133.1%
93.8%
Q3 25
-2272.5%
46.3%
Q2 25
-413.9%
36.3%
Q1 25
-907.4%
28.1%
Q4 24
-2567.7%
98.2%
Q3 24
-244.6%
110.0%
Q2 24
-578.5%
16.8%
Q1 24
-789.9%
-15.0%
Capex Intensity
RXRX
RXRX
SFST
SFST
Q4 25
3.5%
1.8%
Q3 25
4.7%
0.3%
Q2 25
16.4%
0.3%
Q1 25
12.4%
0.5%
Q4 24
28.6%
3.1%
Q3 24
17.5%
0.8%
Q2 24
8.2%
0.4%
Q1 24
48.2%
1.3%
Cash Conversion
RXRX
RXRX
SFST
SFST
Q4 25
Q3 25
1.67×
Q2 25
1.59×
Q1 25
1.44×
Q4 24
Q3 24
6.01×
Q2 24
1.32×
Q1 24
-1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons